Adrenal Diseases

Mouhammed Amir Habra, MD, FACP, FACE
Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders | Division of Internal Medicine
The University of Texas M. D. Anderson Cancer Center | 1400 Pressler Road | Unit 1461 | Houston, TX 77030
Clinic Phone: 713.563.3953
Focus: Adrenocortical Carcinomas
Selected Publications:

Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. European journal of endocrinology / European Federation of Endocrine Societies. 2013;169(6):891-9. Epub 2013/10/03. doi: 10.1530/EJE-13-0519. PubMed PMID: 24086089.
Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Lee JE, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clinical endocrinology. 2014;80(3):342-7. Epub 2013/09/17. doi: 10.1111/cen.12320. PubMed PMID: 24033606.
Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013;98(11):E1813-9. Epub 2013/09/14. doi: 10.1210/jc.2013-1653. PubMed PMID: 24030942.
Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE, Aloia TA. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surgical endoscopy. 2013;27(11):4026-32. Epub 2013/06/15. doi: 10.1007/s00464-013-3034-0. PubMed PMID: 23765427.
Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab. 2013;98(4):1492-7. Epub 2013/02/26. doi: 10.1210/jc.2012-4231. PubMed PMID: 23436918.
Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108(4):826-30. Epub 2013/02/16. doi: 10.1038/bjc.2013.46. PubMed PMID: 23412108; PubMed Central PMCID: PMC3590681.
Cancer Medicine

Vivek Subbiah, MD
Assistant Professor, Department of Investigational Cancer Therapeutics | Division of Cancer Medicine
The University of Texas M. D. Anderson Cancer Center | 1515 Holcombe Blvd. | Unit 455 | Houston, TX 77030
Clinic Phone: 713-792-1160
Focus: Targeted therapy / Personalized Medicine. Phase 1 clinical trials. Sarcoma. Rare diseases. Unusual Responders. N=1 trials.
Selected Publications:

Subbiah V, Brown RE, McGuire MF, Buryanek J, Janku F, Younes A, Hong D. A novel immunomodulatory molecularly targeted strategy for refractory hodgkin’s lymphoma. Oncotarget. 2013;4. Epub 2013/11/19. PubMed PMID: 24395633.
Jardim DL, Conley A, Subbiah V. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Orphanet journal of rare diseases. 2013;8(1):112. Epub 2013/07/31. doi: 10.1186/1750-1172-8-112. PubMed PMID: 23895135; PubMed Central PMCID: PMC3751902.
Subbiah V, Naing A, Brown RE, Chen H, Doyle L, Lorusso P, Benjamin R, Anderson P, Kurzrock R. Targeted Morphoproteomic Profiling of Ewing’s Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures. PLoS One. 2011;6(4):e18424. Epub 2011/04/16. doi: 10.1371/journal.pone.0018424. PubMed PMID: 21494688.
Head and Neck Cancers

Martin J Citardi, MD, FACS
Professor and Chair, Department of Otorhinolaryngology – Head & Neck Surgery
UT Physicians at Memorial Hermann Medical Plaza – UT Oncology | 6400 Fannin St. | Suite 2700 | Houston, TX 77030
Clinic Phone: 713.486.5000
Focus: Sinonasal undifferentiated carcinoma (SNUC). Anaplastic thyroid carcinoma. Alveolar and embryonal rhabdomyosarcoma. Recurrent esthesioneuroblastoma. Recurrent high grade neuroendocrine carcinoma. Recurrent or persistent/refractory high grade salivary gland malignancies.
Selected Publications:

Ansari M, Guo S, Fakhri S, Citardi MJ, Blanco A, Patino M, Buryanek J, Amato R, Karni R, Brown RE. Sinonasal Undifferentiated Carcinoma (SNUC): Morphoproteomic-Guided Treatment Paradigm with Clinical Efficacy. Annals of Clinical & Laboratory Science. 2013;43(1):45-53. PubMed PMID:    23462605
“Morphoproteomics: Driving A Shift To Personalized Care For Sinonasal Undifferentiated Carcinoma”  https://med.uth.edu/orl/newsletter/morphoproteomics-driving-shift-personalized-care-sinonasal-undifferentiated-carcinoma/
Pediatric Oncology
Michael E Rytting, MD
Associate Professor, Pediatrics – Patient Care
The University of Texas M. D. Anderson Cancer Center | 1515 Holcombe Blvd. | Unit 0087 | Houston, TX 77030
Clinic Phone: 713.792.4855
Focus: Leukemia / lymphoma. Relapsed or refractory brain tumors (ependymomas and pontine gliomas).

Johannes Wolff, MD
Chair, Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation
Cleveland Clinic | 9500 Euclid Avenue | Mail Code S20 | Cleveland, OH 44195
Clinic Phone: 216.444.5517
Focus: Medulloblastoma
Selected Publications:

Wolff JE, Brown RE, Buryanek J, Pfister S, Vats TS, Rytting ME. Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatr Blood Cancer. 2012;59(1):27-33. Epub 2011/12/14. doi: 10.1002/pbc.23402. PubMed PMID: 22162424